Human Growth Hormone Help
Fact is that aging is basically the breakdown of cells overtime but when the human body starts to slow don on replacing these miss cells we begin to run into visual signs of aging and in more serious cases, many different health issues.
In the human body our growth hormones are produced by the pituitary gland and stimulates growth and proper body development while we are young and growing. HGH is vital for maintaining proper body functions which includes, tissue repair, muscle growth, brain function, energy, and proper metabolism as we grow.
During our teenage years is when the natural production HGH is at it's highest peaks and slowly decreases as we get older. Even though some people like bodybuilders will choose the accelerate their growth for the purpose of competition doctors will recommend supplementing when patients are growth hormone deficient (GHd).
The FDA approved the supplementing of growth hormones back in 2004, as a medical treatment for poor health conditions including the following...
In adults, wasting (or cachexia) caused by AIDS.
Turner syndrome epitomizes the response of non-deficient shortness. At doses 20% higher than those used in GH deficiency, growth accelerates. With several years of treatment the median gain in adult height is about 2–3 in (5.1–7.6 cm) on this dose. The gains appear to be dose-dependent. It has been used successfully in toddlers with Turner syndrome, as well as in older girls.
SHOX (Short stature homeobox gene) deficiency
Chronic renal failure results in many problems, including growth failure. GH treatment for several years both before and after transplantation may prevent further deceleration of growth and may narrow the height deficit, though even with treatment net adult height loss may be about 4 in (10 cm)
Prader-Willi syndrome, a generally non-hereditary genetic condition, is a case where GH is prescribed for benefits in addition to height. GH is one of the treatment options an experienced endocrinologist may use when treating a child with PWS. GH can help children with PWS in height, weight, body mass, strength, and agility.
Reports have indicated increase of growth rate (especially in the first year of treatment) and a variety of other positive effects, including improved body composition (higher muscle mass, lower fat mass); improved weight management; increased energy and physical activity; improved strength, agility, and endurance; and improved respiratory function.
The Prader-Willi Syndrome Association (USA) recommends that a sleep study be conducted before initiating GH treatment in a child with PWS. At this time there is no direct evidence of a causative link between growth hormone and the respiratory problems seen in PWS (among both those receiving and those not receiving GH treatment), including sudden death. A follow-up sleep study after one year of GH treatment may also be indicated. GH (specifically Pfizer's version, Genotropin) is the only treatment that has received an FDA indication for children with PWS. The FDA indication only applies to children.
Children short condition because of intrauterine growth retardation are small for gestational age at birth for a variety of reasons. If early catch-up growth does not occur and their heights remain below the third percentile by 2 or 3 years of age, adult height is likely to be similarly low. High-dose GH treatment has been shown to accelerate growth, but data on long term benefits and risks are limited.
Idiopathic short stature (ISS) is one of the most controversial indications for GH as pediatric endocrinologists do not agree on its definition, diagnostic criteria, or limits. The term has been applied to children with severe unexplained shortness that will result in an adult height below the 3rd percentile.
In the late 1990s there was an introduction of Gen F20 Plus which was developed as a daily HGH supplement. Another pharmaceutical manufacturer, Eli Lilly and Company sponsored trials of Humatrope (their brand of HGH) to be used for children with extreme ISS, those at least 2.25 standard deviations below mean (in the lowest 1.2 percent of the population). These children expected to acheive a maximum height of less than 63" (160 cm) and 59" (150 cm) respectively.
They were treated for about 4 years and gained 1.5–3 in (3.8–7.6 cm) in adult height. Controversy has arisen as to whether all of these children were truly "short normal" children, since the average IGF1 was low. It was not surprising that approval for this extreme degree of shortness led to an increase in the number of parents seeking treatment to make otherwise healthy children a little taller.